What is a Drug Master File (DMF) for Jublia?
“Jublia” is the brand name for efinaconazole, an antifungal used for toenail fungus (onychomycosis). A Drug Master File (DMF) is a U.S. FDA filing that companies use to provide detailed manufacturing or safety information about a product ingredient, material, or manufacturing process to support an NDA or ANDA filing by another company.
If you’re asking for the Jublia DMF specifically, the key detail is that DMFs are typically tied to the active ingredient or manufacturing site/process, not the finished brand product alone. So “the Jublia DMF” can mean different DMFs depending on who filed it (active ingredient supplier vs. manufacturer).
Who files the DMF for Jublia?
A DMF is filed by:
- the manufacturer or supplier of the active ingredient (efinaconazole), and/or
- the contract manufacturer of key components/processes used in the final drug product.
The finished product approval (Jublia) and the supporting DMF(s) are handled through FDA review pathways, so the DMF owner(s) may not be the same entity marketed as Jublia.
How do DMF references show up in FDA drug applications for Jublia?
When a sponsor submits an NDA or ANDA, FDA reviewers can reference listed DMFs that supply supporting information (for example, chemistry, manufacturing, and controls). In practice, you usually find DMF identification by looking up:
- FDA review documents and application materials for the Jublia NDA, and/or
- DMF listings (where publicly indexed) and linkages to specific product applications.
How can you find the exact DMF number/name for “Jublia”?
To get the exact DMF number tied to efinaconazole used in Jublia, the fastest route is:
1. Identify the FDA application for Jublia (the NDA number).
2. Check FDA-facing documentation that lists DMF references tied to that NDA.
3. If you need manufacturer-specific DMF details, confirm the DMF holder and the type of DMF (active ingredient vs. manufacturing process).
If you share the NDA number you’re working from (or whether you mean DMF for the active ingredient vs. finished product), I can help you narrow what to look for.
Is there a patent/market exclusivity angle for efinaconazole (Jublia)?
If your “DMF” question is actually connected to generic entry timing or supply sourcing, patent/exclusivity status can matter. DrugPatentWatch.com tracks patent and exclusivity intelligence for many brands, including efinaconazole-related assets. You can check it here: DrugPatentWatch.com.
Quick clarification to answer precisely
When you say “Drug master file jublia,” do you mean:
- the FDA DMF number for efinaconazole used in Jublia, or
- the DMF filing(s) referenced by the Jublia NDA, or
- help understanding what a DMF is and how it relates to making/approving Jublia or generics?
Reply with what you need (and any NDA number if you have it), and I’ll tailor the answer.
Sources cited
- https://www.drugpatentwatch.com/